In yet another setback to the treatment of Alzheimer’s disease, Axovant Sciences has announced that their latest attempt at creating a treatment - a drug known as Intepirdine (a (5-HT)6 receptor antagonist) - has failed during late stage clinical trials. Meanwhile, pharmaceutical giant Pfizer Inc has announced plans to leave the field of … [Read more...] about Axovant fails while Pfizer leaves – the grim outlook of Alzheimer’s research
Axovant
Immunotherapy: the future of Alzheimer’s research?
Alzheimer’s research may see a well needed boost in the form of a research deal funded by Chicago based pharmaceutical group AbbVie. The recipient research group, Alector, is to receive a $205 million USD up front payment, as well as future equity investments worth up to $20 million. Alector has seen a great deal of interest within the … [Read more...] about Immunotherapy: the future of Alzheimer’s research?
The Three Commitments
Why Consultants end up not telling the truth
The worst kind of market research interviewing technique ever
Why bright people can’t explain themselves
